COVID-19 in lung-transplanted and cystic fibrosis patients: Be careful

Farfour, Éric; Picard, C.; Beaumont, L.; Lesprit, Philippe; Ballester, Marie; Ackermann, Félix; Galliot, Richard; Verdière, Sylvie Colin de; Cerf, Charles; Vasse, Marc

doi:10.1016/j.jcf.2020.03.021

Cited by 15 publications

(20 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the secondary screening of 122 full texts, we excluded 72 papers. Finally, 50 studies, including 36 case reports, and 14 case series which overall have presented 337 patients were included in this systematic review 3,7,12‐57 . The studies of Qin, L et al and Zhong, z et al reported a same case; to avoid duplication bias, we excluded (Qin, L et al) from our review.…”

Section: Resultsmentioning

confidence: 99%

COVID‐19 clinical manifestations and treatment strategies among solid‐organ recipients: A systematic review of cases

Moosavi

Mashhadiagha

Motazedian

et al. 2020

Transplant Infectious Dis

View full text Add to dashboard Cite

Background COVID‐19 has been spreading worldwide with a significant death toll. Solid‐organ transplantation (SOT) recipients are at higher risk due to their suppressed immune system. In this study, we aimed to conduct a systematic review on COVID‐19 clinical manifestations and treatment strategies in SOT recipients. Methods We searched three databases for relevant terms related to COVID‐19 and transplantation. 50 studies, including 337 patients, were reviewed. Results 236 patients were male, with a mean age of 49.9 years. The most prevalent group was the kidney 57.0%, followed by 17.2% heart, and 13.6% liver. Fever and Cough were the most reported clinical presentations. Infiltration (55.4%) in chest x‐ray and ground‐glass opacity (67.1%) in CT scans were the most radiological findings. It was found that 96.8% and 72.4% of patients present with CRP level and lymphocytopenia, respectively, and 70.6% of kidney recipients patients presented with high creatinine levels. The most common baseline immunosuppressants were Calcineurin inhibitors (88.9%), and antimetabolites (73.2%). Antimetabolites (84.3%) and Calcineurin inhibitors (54.3%) were discontinued/decreased 84.3% whereas glucocorticoids dosage almost have no change (77.9%) or even increased. 18.4% of cases had died, and 65.9% were discharged. Conclusions Patients’ demographics, signs, symptoms, and radiographic findings in SOT recipients are almost similar to the general population. However, gastrointestinal symptoms appear to be more common. There are different treatment strategies, but in most of them, antimetabolite and Calcineurin inhibitors were decreased or discontinued, while corticosteroids were increased. Finally, Covid‐19 seems to be more severe and has higher mortality in SOT recipients compared to the general population.

show abstract

Section: Resultsmentioning

confidence: 99%

COVID‐19 clinical manifestations and treatment strategies among solid‐organ recipients: A systematic review of cases

Moosavi

Mashhadiagha

Motazedian

et al. 2020

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Furthermore, as SARS-CoV-2 viral load in respiratory sample decrease with the duration of the disease [4], it is likely the patients presenting some days after the onset of the symptoms could display a negative RT-PCR result. Elsewhere, it was suggested upper respiratory tract samples could remain negative in almost exclusive pulmonary diseases [10].…”

mentioning

confidence: 99%

SARS-CoV-2 RT-PCR and Chest CT, two complementary approaches for COVID-19 diagnosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…8 The number of telehealth visits at a single academic institution in Ohio increased from less than 100 visits per day to over 2200 daily visits over 24 days following the start of the pandemic. 9 Physical distancing is particularly important for patients with CF who may be predisposed to severe manifestations of COVID-19 due to their comorbidities 10 and for whom recommendations for strict infection control have long been in place even prior to COVID- 19. 11 Potential Use of Telehealth in CF Centers During COVID -19 Telehealth has been explored as a way to circumvent these barriers to care while still ensuring that patients receive the good quality, multidisciplinary care and frequent monitoring that has been associated with good outcomes.…”

Section: Impact Of Covid-19 On Cf Center Carementioning

confidence: 99%

<p>Emerging Alternatives to Conventional Clinic Visits in the Era of COVID-19: Adoption of Telehealth at VCU Adult Cystic Fibrosis Center</p>

Womack¹,

Farsin²,

Farsad³

et al. 2020

IJGM

View full text Add to dashboard Cite

COVID-19 in lung-transplanted and cystic fibrosis patients: Be careful

Cited by 15 publications

References 4 publications

COVID‐19 clinical manifestations and treatment strategies among solid‐organ recipients: A systematic review of cases

COVID‐19 clinical manifestations and treatment strategies among solid‐organ recipients: A systematic review of cases

SARS-CoV-2 RT-PCR and Chest CT, two complementary approaches for COVID-19 diagnosis

<p>Emerging Alternatives to Conventional Clinic Visits in the Era of COVID-19: Adoption of Telehealth at VCU Adult Cystic Fibrosis Center</p>

Contact Info

Product

Resources

About